Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled Phase II trial of TAK-360 in narcolepsy type 1 with cataplexy
CTR20261964Phase 2Active
- Sponsor
- Takeda
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in narcolepsy type 1 (NT1) comparing TAK-360 with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs). Started Jul 2026; status: active.
02
Drugs
TAK-360
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on CTR20261964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261964.